Intrance Medical Systems is a subsidiary of Sweden‑based Intrance Holdings AB focused on developing and commercializing its lead product, Lecigon®, a fixed‑dose combination of levodopa, carbidopa and entacapone for enteral infusion in advanced Parkinson’s disease patients. The product is currently marketed as Lecigon® in the Nordic countries and certain European markets. The company recently filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration and plans to advance a U.S. clinical development program. Proceeds from the recent financing will enable initiation of pivotal U.S. clinical trials. Intrance says it is targeting commercialization in the U.S., Canada, South America, Japan and Taiwan. The company is privately held and emphasizing clinical and regulatory milestones to support U.S. expansion. Intrance Medical Systems is a private biopharmaceutical company and a subsidiary of Sweden‑based Intrance Holdings AB, established in 2018 as a spin‑out from Lobsor Pharmaceuticals AB. Its lead product is a fixed‑dose combination of carbidopa, entacapone and levodopa for enteral infusion, marketed in Europe as Lecigon®. The product system is commercialized in Europe by STADA/Britannia (which acquired Lobsor in September 2020) and is commercially launched in several key markets, reportedly gaining market share and user acceptance. Intrance owns patents and patent applications covering the U.S., Canada and Japan and holds commercial rights in South/Central America. The company has filed an Investigational New Drug (IND) application with the U.S. FDA and plans to initiate a U.S. clinical development program. The recently secured funding will be used to initiate that U.S. clinical program.

Total raised

$32M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2022